Partner with the Leaders
Building Medtech
Trusted By The Companies Pioneering What’s Next
The Global Stage for
Live-Saving Innovation
In 2025, LSI USA convened 1,600 executives from emerging companies, venture capital and private equity firms, family offices, global strategics, professional service providers, and more.
Too many events are light on real investors. That’s why we’ve built deep, lasting relationships with active VCs, PEs, and CVCs. and create an experience they show up for, year after year.
We’re continuing to push the bar. This year, we are thrilled to have Peter Hebert, Co-Founder and Managing Partner of Lux Capital, share perspective on his vision for a new wave of bigger, better financial and patient outcomes in medtech.
Connect with industry-leading executives from emerging
companies,
venture capital and private equity firms, family
offices, investment
banks, global strategics, and more.
Present to a full house of investors and strategics
alongside the CEOs and Founders building
technology that is shaping the future of healthcare.
-
LifeSignals has created wireless patient monitoring solutions for population health management based on its distinguished wearable multi-parameter vital sign Biosensors made possible by a patented purpose-built system-on-silicon chip with embedded AI engine. LifeSignals real-time monitoring platform enables hundreds of thousands of Biosensors communicating with cloud-based software generating AI driven alerts in real time, serving applications such as in-hospital multiparameter monitoring, hospital-at-home, mobile cardiac telemetry (MCT) and cardiac Holter monitoring. Visit website.
Surendar Magar
CEO
-
Why not use technology to reduce the risk of chronic use and addiction when prescribing addictive medications, while also saving valuable time for healthcare professionals? Prescriby is a data-driven treatment management platform designed for addictive medications. It provides a safe and efficient solution for health clinics managing and prescribing substances like opioids and benzodiazepines. Visit website.
Kjartan Thorsson
CEO
-
Intrinsic Therapeutics is a commercial-stage medical device company dedicated to reducing reoperations for patients undergoing lumbar discectomy. The company's flagship product, Barricaid, is the only PMA-approved device designed to close annular defects following discectomy, the most commonly performed spine procedure. Barricaid has met safety and efficacy requirements, resulting in a dedicated C-Code for facility payment, a series of ICD-10 diagnostic codes, and a recently established Category 1 CPT code for physician reimbursement. Visit website.
Cary Hagan
President & CEO
-
Pulsli have created an AI-enabled fluid overload predictor in patients with congestive heart failure. The clinically validated technology provides noninvasive remote patient self-monitoring, improving user engagement and reducing the workload of health professionals. Visit website.
Sasha Banjac
CEO & Founder
-
Imaginostics is developing next-generation diagnostic solutions to support clinicians and drug developers. The company’s QUTE-CE MRI technology is a noninvasive quantitative imaging solution that enhances existing MRI machines with quantitative measuring capabilities to measure vascular function and structure. Imaginostics is actively utilizing its technology in pre-clinical and clinical research in the fields of cardiology, oncology and neuroscience. Visit website.
Codi Gharagouzloo
CEO
-
GenesisTissue is developing regenerative breast tissue using advanced 3D bioprinting technology. The technology combines a bioprinted personalized breast scaffold with the patient’s own fat cells to create an engineered tissue solution that regenerates. By combining presurgical planning, plan-specific guidance, and personalized implant design, GenesisTissue aims to advance breakthroughs in tissue engineering for reconstructive and cosmetic breast indications, with potential for broader soft tissue applications.
Katie Weimer
CEO & Co-founder
-
BRIJ Medical develops advanced solutions for incision closure, wound support, and scar therapy. The company’s flagship product, the Brijjit® Force Modulating Tissue Bridge, has been clinically proven to reduce wound breakdown and scar formation by minimizing tension on healing tissues. Designed for efficiency, it enables faster closure compared to traditional sutures and offers a cost-effective option for surgeons, ambulatory surgery centers, and hospitals. Visit website.
Tim Gleeson
CEO and Board Member
-
Calla Lily Clinical Care is a women's health focused company which has developed the proprietary Callavid® platform for intravaginal drug delivery. Initial target indications are in IVF and miscarriage prevention, followed by delivery of live biotherapeutics (LBPs) to reduce antibiotic usage which contributes to antimicrobial resistance (AMR). Further use-cases include effective sample collection to facilitate the next generation of biomarker-based diagnostic tests for endometriosis and a wide range of other conditions. Visit website.
Lara Zibners
Co-Founder & Chairman
-
DeepSight Technology develops advanced medical imaging solutions using proprietary sensing technology to enhance diagnostic ultrasound capabilities. The company’s NeedleVue Technology is designed to improve ultrasound-assisted needle guidance, addressing challenges such as complex calibration, reduced sensitivity, and angle dependence. By integrating innovative sensor technology with interventional devices, NeedleVue enables real-time verification of device placement, aiming to reduce procedural uncertainty and streamline interventional workflows. DeepSight Technology operates from the San Francisco Bay Area and Clayton, Missouri, with a focus on expanding the range and effectiveness of diagnostic ultrasound. Visit website.
Diku Mandavia
CMO
-
Quantanosis is pioneering stroke care with an AI-powered device that integrates imaging and histotripsy to rapidly diagnose and treat major ischemic strokes, with strong results in animal models and plans to enter first-in-human trials. Its fully automated system is designed to enhance outcomes at leading stroke centers while also enabling hospitals without round-the-clock neuro specialists to deliver advanced stroke interventions, bridging critical gaps in access to care. With $4 million in initial backing from 30 key opinion leaders in neurology, neurosurgery, and neurointervention, Quantanosis is now seeking institutional investors as it advances toward pivotal clinical trials Visit website.
Ameer E. Hassan
CEO and Co-Founder
-
Juniper Biomedical is developing a precision neuromodulation micro-implant to treat pelvic health conditions. Visit website.
David Constantine
CEO
-
UNEEG Medical A/S develops cognitive technologies for continuous brain activity monitoring (EEG) to support medical and diagnostic applications. The company specializes in ultra long-term subcutaneous EEG monitoring with its CE-marked 24/7 EEG™ SubQ solution, designed to detect electrographic seizures in daily life. UNEEG’s technology provides objective insights into seizure burden for epilepsy management and aims to alert diabetics of severe hypoglycemia. The company employs approximately 100 people and has recently begun an international market launch. Visit website.
Martin Stenfeldt
CEO
-
Spiro Robotics is developing an innovative handheld robot intended to automate airway management in patients requiring tracheal intubation. Visit website.
Dimitri Sokolov
CEO
-
Field Orthopaedics is dedicated to developing innovative products to meet the needs of complex fracture management, arthritis and microsurgery. The company's portfolio of cannulated screws and intramedullary nailing system address the challenges critical to advancing hand surgery. Visit website.
Patryk Kania
CEO and President
-
EP Solutions is improving clinical outcomes in cardiac resynchronization therapy cases through the use of noninvasive cardiac mapping technology. The company's Amycard 01C is an electrophysiology workstation that records body surface electrograms to create optimized 3D heart models that merge ECG data with anatomical data obtained from medical imaging. EP Solutions' technology helps physicians accurately place CRT leads during implantation and optimize devices during follow-up visits. Visit website.
Marcin Golebicki
CEO
-
AutoMedicus Corporation has developed a transformative closed-loop blood pressure control device, called the AutoPress, for use in the OR and ICU. The AutoPress was recently designated as a Breakthrough device by the FDA (CDRH). Visit website.
William "Bill" Harrity, M.D.
Chief Medical Officer and Co-Founder
-
Solaris Endovascular, Inc. is a growth stage, US-based medical device company developing advanced endovascular solutions for patients suffering from dialysis access challenges and Peripheral Artery Disease. With a proven stent platform and innovative drug-eluting technology, led by seasoned executives with extensive experience in cardiovascular MedTech, Solaris Endovascular is uniquely positioned and committed to improving long-term patient outcomes and transforming vascular health. Visit website.
Randy Hubbell
President & CEO
-
Vena Vitals is an early stage med-tech company focused on non-invasive continuous blood pressure monitoring. The company's proprietary technology is a soft flexible sensor that conforms to the skin for direct pressure measurement at theradial artery. The company's technology is intended to replace unnecessarily invasive arterial line measurements as well as non-continuous cuff-based methods in both the hospital and at home. Visit website.
Ray Liu
CEO & Co-Founder
-
Vergent’s lead compound, abenacianine for injection (VGT-309), is a next generation tumor-targeted fluorescent imaging agent for cancer surgery designed to provide real-time, intraoperative visual and molecular feedback on tumor location and help surgeons ensure all tumor tissue is removed during minimally invasive surgery (MIS) procedures. Abenacianine is designed to be an ideal targeted imaging agent and is compatible across NIR enabled surgical visualization platforms, works across all solid tumor types, and has a differentiated mechanism of action that allows for a wide dosing window to seamlessly fit into surgery workflows. Visit website.
John Santini
President & CEO
-
The TriPair™ Technology is a novel minimally invasive tricuspid repair solution designed to treat Tricuspid Regurgitation —a condition that affects millions globally, with the vast majority currently remaining untreated. TriPair™ simplifies transcatheter repair through an innovative edge-to-spacer approach, aiming to reduce procedural complexity and improve access to care. TriPair™ is designed to be simple, fast (procedure time under 30 minutes), and highly effective, empowering physicians in both established and underserved markets to treat patients who cannot be helped with existing technologies. Following a successful first-in-human trial, TriPair™ is now being prepared for evaluation in global feasibility studies across multiple continents. Visit website.
Jochen Reinöhl
CEO
-
The Somavac system is designed to apply deep tissue Negative Pressure Therapy to reduce and prevent the occurrence of seroma in patients who have recently undergone breast reconstruction and mastectomies. Somavac is intended to reduce post-operative complications and the time requiring surgical drains following surgery. The system is self-contained within a belt to discretely remove fluid and prevent build-up that can lead to complications. Visit website.
Elizabeth Hoff
Board Member
-
Hy2Care's vision is to support patients in the fight against osteoarthritis. The company's lead product, CartRevive, is a hydrogel implant composed of dextran and hyaluronic acid conjugates that form a resorbable scaffold when injected. The hydrogel enables natural restoration of tissue defects by creating an environment conducive to cell regrowth that proceeds towards the restoration of smooth hyaline cartilage. Visit website.
Leo Smit
CEO
-
Tensor Surgical develops technologies for orthopedic soft tissue repair sports medicine. The company’s portfolio of products consists of solutions to simplify and reduce the cost rotator cuff repair and bicep tenodesis procedures. Visit website.
Justin Anderson
CEO
-
Adaptyx Biosciences, a Stanford University spin-off, is building a biomonitoring platform that leverages 15 years of research in molecular switches and microarray patches, enabling minimally-invasive real-time, continuous sensing of small molecules and proteins. Adaptyx's library of multi-analyte sensors will enable deeply personalized medicine across drug dosing, hormone regulation, kidney health, cardiovascular disease, and oncology.
Vijit Sabnis
Co-Founder
-
InkSpace Imaging pioneers a transformative printed electronics platform, initially prioritizing advanced MRI receive coils. These lightweight and flexible coils not only elevate diagnostic imaging, revealing the once invisible, but also expedite scans, enhance patient experiences, reduce the need for sedation, and minimize procedures. Compatible with existing MRI systems and healthcare reimbursement structures, the company's FDA-cleared innovation represents a next-generation approach to accessible, high-quality diagnostics. Visit website.
Peter Fischer
CEO
-
Arsenal Medical develops innovative biomaterials to solve challenging and underserved medical problems. Our lead products target neurovascular and trauma conditions providing control of blood flow to tumors and bleeding conditions, such as hemorrhage. Visit website.
Upma Sharma
President & CEO
-
SamanTree Medical's Histolog Scanner is a digital microscopy scanner for high-resolution imaging of the surface of fresh tissue. The device utilizes novel, ultra-fast confocal microscopy technology to enable rapid histological assessment in the operating room or pathology laboratory. Visit website.
Olivier Delporte
CEO
-
Nutromics is pioneering Continuous Molecular Monitoring (CMM), a real-time biomarker monitoring platform that offers molecular patient data. The technology integrates into a wearable smart patch that continuously captures and transmits data to mobile and web-based applications for easy integration with hospital and consumer health software. Visit website.
Peter Vranes
CEO
-
Axena Health is dedicated to improving the lives of women with pelvic floor disorders. The company's Leva Pelvic Health system helps women train and strengthen their pelvic floor muscles from their homes to improve the management of stress, mixed, and mild-to-moderate urinary incontinence and chronic fecal incontinence. Visit website.
Jim O'Connor
General Counsel & Chief Financial Officer
-
iO Urology aims to improve the lives of people living with urologic conditions. The company’s CarePath device is a remote patient monitoring system to promote urologic care at home. CarePath provides real-time, quantitative measurement of urinary output and flow to support the management of lower urinary tract symptoms from conditions such and benign prostatic hypertrophy and overactive bladder. Visit website.
Britton Garrett
CEO
-
Prevencio develops personalized blood tests designed to improve the early detection and prevention of cardiovascular disease. Using machine learning, multi-proteomic biomarkers, and proprietary algorithms, Prevencio’s technology aims to provide more accurate diagnostic and prognostic insights than traditional methods. The company's patented tests have been published in leading cardiology journals and presented at major cardiovascular conferences. Prevencio’s approach is intended to reduce unnecessary procedures and improve patient outcomes. Visit website.
Rhonda Rhyne
CEO
-
FundamentalVR offers an Immersive VR platform for specialty suite procedures and is a strategic partner helping med-device leaders to solve the Competency at Scale Gap. Through its purpose-built immersive VR platform, FundamentalVR provides high-fidelity VR, including unique HapticVR capabilities, for the precision of specialty surgeries, as well as behavioral telemetry and assessment data for AI/ML-driven insights. Visit website.
Richard Vincent
CEO
-
Gyder Surgical's Gyder Hip System is a non-invasive, pin-less navigation solution for total hip replacement. The system is an open platform that can be used with a surgeon's preferred implant system, reduces radiation exposure by not requiring CT or X-ray imaging, and seamlessly integrates into existing workflows due to the system's simple set-up and quick calibration. Visit website.
Sujit Dike
CEO
-
Autonomix (Nasdaq: AMIX) is a medical device company developing a minimally invasive nerve-sensing, ablation, and verification system to advance the diagnosis and treatment of diseases involving the nervous system. The company’s catheter-based microchip sensing array is designed to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than existing technologies. This platform enables transvascular diagnosis and treatment of conditions affecting the peripheral nervous system. Initially focused on pancreatic cancer pain, Autonomix’s technology has potential applications across multiple fields, including cardiology, renal denervation, and chronic pain management. Visit website.
Brad Hauser
CEO
-
Flow Medical is developing a novel thrombolytic catheter for the treatment of pulmonary embolism. The device will combine imaging, infusion, and monitoring into a single solution to streamline procedures, improve therapeutic efficacy, and reduce inventory needs. Visit website.
Jennifer Fried
CEO
-
Lazzaro Medical has developed a minimally invasive surgery for the treatment of Tracheobronchomalacia (TBM), a degenerative disease that causes the complete, or near-complete, collapse of the airway due to cartilage breakdown in the trachea. The LM Scaffold System restores the patency of the trachea, improving breathing through a simple procedure conducted via a robotic system. The company is pursuing a platform approach to the treatment of TBM and other pipeline indications with the development of a diagnostic tool to simplify diagnosis and an endotracheal tube to improve the efficiency of respiratory surgeries. Visit website.
Dawn Bitz
President
-
THINK Surgical develops and commercializes robotic surgery systems for the orthopedics market. The company's TSolution One is indicated for total knee arthroplasty. The system is capable of fully automated bone preparation that is personalized and prepared utilizing proprietary planning tools to achieve optimal fit of the selected knee implant. Visit website.
Stuart Simpson
CEO
-
Clairity develops AI-driven tools to enhance breast cancer screening and risk assessment. Its platform utilizes deep learning models to analyze mammographic images, aiming to improve early detection, reduce racial and ethnic biases, and personalize care plans. The technology is grounded in decades of research led by Dr. Connie Lehman at institutions such as Mass General Brigham and MIT. Clairity's approach seeks to transform mammography from a one-size-fits-all model to a precision medicine framework. Visit website.
Jeff Luber
CEO
-
URO-1is an emerging medtech company developing proprietary surgical solutions for office-based urology. The company is targeting the challenges associated with inadequate biopsy, which can lead to increased costs, procedure duplication, and diagnostic delay. The SUREcore and coreCARE platforms are two solutions within the company’s portfolio that are intended to improve the standard of care in prostate biopsy and other soft tissue biopsy procedures. Visit website.
Ted Belleza
CEO
-
Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. Through its AI-based, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency. Visit website.
Rob Krummen
CEO
-
28% of adults in the United States reported having chronic low back pain, yet current surgical treatments have unacceptably low success rates. Aposture Surgical has developed and clinically proven two radically different solutions to break this cycle of failure: an ultra-minimally invasive treatment for lumbar spinal stenosis and a novel fixation system for spinal fusion. Moreover, Aposture Surgical seeks to transform spinal surgery with its AI-enabled navigation system and robotic surgery platform to guide its surgical procedures. Visit website.
John H. Chung
Co-Founder & CEO
-
Anaut is a Tokyo-based technology company that is passionate about using the power of AI to drive innovation in the healthcare industry. Our mission is to revolutionize surgery by developing AI precision mapping technology that can improve surgical outcomes and reduce the risk of complications. Our flagship product, Surgical Vision EUREKA, is a game-changing solution that has been specifically designed to support this mission. EUREKA uses cutting-edge algorithms and deep learning methodologies to achieve real-time precision mapping of the surgical field, allowing surgeons to navigate through complex anatomical structures with greater precision and accuracy. By leveraging the power of AI, we believe that we can transform the surgical landscape and provide better outcomes for patients around the world. Visit website.
James Grosvenor
VP of Global Operations
-
CygnusMed is advancing endovascular care with a novel hemostatic valve designed to provide continuous, uninterrupted sealing of the guiding catheter during interventions. The device enables arterial blood pressure monitoring without the need for a second arterial line, minimizes blood loss, and supports continuous saline flushing of the catheter to significantly reduce the risk of iatrogenic emboli. By addressing critical challenges in endovascular procedures, CygnusMed's innovative solution enhances safety, efficiency, and patient outcomes. Visit website.
Firas Al-Ali M.D.
Founder and CEO
-
Rekovar develops wearable biosensor technology aimed at improving the management of Neonatal Abstinence Syndrome (NAS). Its flagship product, NeoMonki, is an investigational neonatal monitoring kit designed to provide real-time, objective data on infants' physiological and behavioral states. The system includes a wristband sensor, imaging camera, tablet application, and a provider portal, enabling healthcare professionals to deliver personalized care and intervention. Visit website.
Shiva Sharareh
CEO
-
Nitinotes develops the EndoZip™, the first fully automated endoscopic suturing system for Endoscopic Sleeve Gastroplasty (ESG), a minimally invasive weight-loss procedure. Designed for efficiency, EndoZip enables a single-operator ESG procedure with automated, standardized suturing, reducing variability, procedure time, and training requirements. The system facilitates outpatient treatment with low-risk and predictable outcomes, addressing the growing need for effective, non-surgical obesity interventions. Visit website.
Offer Nonhoff
CFO
-
Solenic Medical is developing a non-invasive medical device that utilizes alternating magnetic fields to eradicate biofilms that form on implants. The company's platform uses external magnetic coils to destroy infective biofilms on the surface of knee and hip replacement implants, as well as plates and rods for trauma related procedures. Solenic's solution is being developed to replace the expensive and risky two-step revision surgery, which is the current standard of care for chronic infections on medical implants. Visit website.
James Lancaster
CEO
-
Osheru has developed innovative technology using compression skin contouring to remove excess unwanted skin. Our first product, the Ziplyft, makes an eyelid lift minimally invasive and easier on the surgeon and the patient, increasing efficiency by eliminating the need for cautery and suturing. With Ziplyft, surgeons can offer a premium experience to their patients and patients benefit with a natural refreshed look with improved symmetry, reduced downtime, and faster recovery than traditional blepharoplasty. At Osheru we are ‘Opening Eyes Beautifully'. Visit website.
Patricia Buehler
CEO & Founder
-
EndoInnovate is developing a new oral colonoscopy preparation designed to improve the detection of subtle polyps and enhance colon cancer prevention. The product has shown promising results in human pilot studies and follows a strategic FDA 505(b)(2) regulatory pathway. With strong intellectual property protection and significant market potential, EndoInnovate is seeking seed funding to advance this technology and improve patient outcomes in colorectal cancer screening. Visit website.
Toufic Kachaamy
Founder
Don't take our word for it.
Explore real success stories
Sponsorship opportunities
Elevate your brand and
accelerate growth at the
epicenter of the industry

sessions from previous events, captivating photos, and the latest
alumni news. Dive in today to prepare for your next LSI experience.



